Levin Capital Strategies, L.P. Eye Point Pharmaceuticals, Inc. Transaction History
Levin Capital Strategies, L.P.
- $990 Million
- Q2 2025
A detailed history of Levin Capital Strategies, L.P. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 19,000 shares of EYPT stock, worth $201,020. This represents 0.02% of its overall portfolio holdings.
Number of Shares
19,000
Previous 43,000
55.81%
Holding current value
$201,020
Previous $233,000
23.61%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding EYPT
# of Institutions
165Shares Held
72.4MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$88.1 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$72 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$65.6 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$43.9 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$43.2 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $360M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...